A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...

Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.

New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or ...

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...

An estimated $133 million to $336 million worth of lecanemab may be discarded every year. Adding a 75-mg vial could save ...

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...

Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...

Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...

Biogen (BIIB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit Bansal ...

While Alzheimer’s can’t be reversed, Leqembi has proven that it can slow down the progression of the disease.

While the uptake in Leqembi, their Alzheimer’s product, has been slow, we still see strong long-term potential for a patient population that is dramatically underserved. We find the risk/reward ...

It’s the first time, according to the insurer, that this type of model has been used to bring a Humira biosimilar to market, and it yields a much lower cost than both the brand-name version of the ...